PULMOTECT, INC
HOUSTON, TX · CIK 0001673929 · Biotech · Private
Inhaled therapeutic that stimulates innate immune response in lungs against pathogens
pulmotect.com →- Grants
- $7.0M
- 5 awards
- Sector median: 1
- Raised
- $22M
- 6 Form D · Sep 2024
- 25 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 1
- 0 granted · 1 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201420162018202020222024
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · Expanding the Market and Success Rates for Myeloablative Cancer Treatments Using PUL-042, an Innate Immune Stimulant | $982,488 | |
| Federal grant | Department of Health and Human Services · Phase II · Expanding the Market and Success Rates for Myeloablative Cancer Treatments Using PUL an Innate Immune Stimulant | $2,980,030 | |
| Federal grant | Department of Health and Human Services · Phase II · Preventing and treating RSV pneumonia in immunocompromised cancer patients | $999,372 | |
| Federal grant | Department of Health and Human Services · Phase II · Expanding the Market and Success Rates for Myeloablative Cancer Treatments Using PUL-042, an Innate Immune Stimulant | $998,771 | |
| Private capital raised | Form D · SEC | $1,751,430 | |
| Federal grant | Department of Health and Human Services · Phase II · Expanding the Market and Success Rates for Myeloablative Cancer Treatments Using PUL-042, an Innate Immune Stimulant | $998,771 | |
| Private capital raised | Form D · SEC | $4,000,003 | |
| Private capital raised | Form D · SEC | $3,500,000 | |
| Private capital raised | Form D · SEC | $2,211,000 | |
| Private capital raised | Form D · SEC | $300,000 | |
| Private capital raised | Form D · SEC | $10,280,435 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2465 | Abzena plc | — | $4.3M |
| 2466 | CURADEL SURGICAL INNOVATIONS, INC. | — | $24M |
| 2467 | Vaxart, Inc. | — | $23M |
| 2468 | PULMOTECT, INC | — | $22M |
| 2469 | New Echota Biotechnology | — | — |
| 2470 | Rocket Pharmaceuticals Ltd. | — | $28M |
| 2471 | BIOSTRATEGIES LC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Mark BenedykDirector
- Colin BroomDirector · Executive Officer
- James GamettDirector
- Bruce GivenDirector
- Magnus HookDirector
- Leo LinbeckDirector
- Leo Linbeck IIIDirector
- William NossExecutive Officer
- Brenton ScottDirector · Executive Officer · Promoter
- Kumar SrinivasanDirector
- Atul VaradhacharyDirector
- Mark WorschehDirector
Patents
- Compositions And Methods For Treating Viral Infections Through Stimulated Innate Immunity In Combination With Antiviral Compoundsapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.